Tyro3
Tyro3 is a member of the TAM (TYRO3, AXL, MER) receptor tyrosine kinase family, which plays critical roles in immune regulation and phagocytosis. It is primarily expressed in the central nervous system and has been implicated in neuroinflammation and neurodegenerative diseases[1]. Tyro3 functions as a receptor for phosphatidylserine (PS), mediating the clearance of apoptotic cells through efferocytosis[2]. This process is essential for maintaining tissue homeostasis and preventing autoimmunity[3]. Recent studies have shown that Tyro3 signaling contributes to microglial quiescence and suppresses pro-inflammatory responses in the brain[4]. Furthermore, dysregulation of Tyro3 has been associated with pathological conditions such as Alzheimer’s disease and multiple sclerosis[5].
References:
- [1]. Bordon Y. Microbiota: Gut bacteria cross malaria. Nat Rev Immunol. 2015 Jan;15(1):1. doi: 10.1038/nri3796. PMID: 25534616. et al. Microbiota: Gut bacteria cross malaria. Nat Rev Immunol. 2015 Jan;15(1):1. [Content Brief]
- [2]. Kleaveland B, et al. A Network of Noncoding Regulatory RNAs Acts in the Mammalian Brain. Cell. 2018 Jul 12;174(2):350-362.e17. [Content Brief]
- [3]. Kiros M, et al. Trends in HIV-1 pretreatment drug resistance and HIV-1 variant dynamics among antiretroviral therapy-naive Ethiopians from 2003 to 2018: a pooled sequence analysis. Virol J. 2023 Oct 25;20(1):243. [Content Brief]
- [4]. Tasaka GI, et al. The Temporal Association Cortex Plays a Key Role in Auditory-Driven Maternal Plasticity. Neuron. 2020 Aug 5;107(3):566-579.e7. [Content Brief]
All Product Categories
-
Tyro3 Related Products (12)
- 1
-
BMS 777607
0 ImagesSynonyms: BMS 817378BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity versus all other receptor and non receptor kinases. -
loading...loading...
-
-
LDC1267
0 ImagesLDC1267 is a AXL/TAM/FLT3 inhibitor with IC50 values of 42 nM, 130 nM, and 63 nM against AXL, MERTK, and TYRO3, respectively. LDC1267 blocks GAS6-induced AXL phosphorylation and the downstream AKT/ERK1/2 signaling pathway. LDC1267 inhibits cancer cell proliferation, colony formation, and glioblastoma cell invasion, without causing obvious impairment of cytotoxic autophagic flux. LDC1267 exerts a synergistic effect when used in combination with Imatinib (HY-15463) in chronic myeloid leukemia models. LDC1267 can be widely applied in studies related to glioblastoma and chronic myeloid leukemia. -
loading...loading...
-
-
UNC569
0 ImagesUNC569 is a potent, reversible, ATP-competitive and orally active Mer kinase inhibitor with an IC50 of 2.9 nM and a Ki of 4.3 nM. UNC569 also inhibits Axl and Tyro3 with IC50s of 37 nM and 48 nM, respectively. UNC569 can be used for acute lymphoblastic leukemia (ALL) and atypical teratoid/rhabdoid tumors research -
loading...loading...
-
-
Tamnorzatinib
0 ImagesSynonyms: ONO-7475Tamnorzatinib (ONO-7475) is a potent, selective, and orally active Axl/Mer inhibitor with IC50 values of 0.7 nM and 1.0 nM, respectively. Tamnorzatinib sensitizes AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs, suppresses the emergence and maintenance of tolerant cells. Tamnorzatinib combines with Osimertinib (HY-15772) provides a bright promise for the study of EGFR-mutated non-small cell lung cancer (NSCLC). -
loading...loading...
-
-
UNC9426
0 ImagesUNC9426 is a potent and selective TYRO3 inhibitor (IC50 = 2.1 nM), demonstrating 276-fold and 90-fold selectivity over MERTK and AXL, respectively. UNC9426 reduces platelet aggregation without increasing bleeding time and blocks TYRO3-dependent functions in tumor cells and macrophages. UNC9426 demonstrates a favorable safety profile with no significant increase in bleeding risk in vivo. UNC9426 can be used for functional studies of TYRO3-dependent phenotypes such as non-small cell lung cancer (NSCLC). -
loading...loading...
-
-
UNC1062
0 ImagesUNC1062 is a highly selective tyrosine kinase (MERTK) inhibitor with an IC50 of 1.1 nM (Morrison Ki = 0.33 nM). UNC1062 exhibits good selectivity for the TAM family (TYRO3 IC50 = 60 nM, AXL IC50 = 85 nM). UNC1062 exhibits significant anti-proliferative effects and induces apoptosis in various cancer models (such as melanoma, gastric cancer, and acute myeloid leukemia). UNC1062 inhibits multiple pathways, including MAPK/ERK, PI3K/AKT and JAK/STAT and affects the motility of head and neck squamous cell carcinoma (HNSCC) cells through the RhoA signaling pathway. UNC1062 inhibits macrophage efferocytosis, and it suitable for research on atherosclerosis. -
loading...loading...
-
-
PF-07265807
0 ImagesCat. No.: HY-147218CAS No.: 2412356-57-9Synonyms: ARRY-067PF-07265807 (ARRY-067) is a kinase inhibitor with primary targets AXL, MERTK, and TYRO3. PF-07265807 acts as an immunomodulator that cross-activates CD8+ T cells by enhancing dendritic cell function. PF-07265807 blocks downstream signal transduction of AXL and MERTK, and inhibits the proliferation and migration of tumor cells with high expression of these two kinases. PF-07265807 is applicable to research related to advanced or metastatic solid tumors, such as colorectal cancer. -
loading...loading...
-
- UNC4203
-
loading...loading...
-
-
UNC8212
0 ImagesCat. No.: HY-173400UNC8212 is a TAM kinase inhibitor. UNC8212 has potent inhibitory activity against MERTK and AXL (IC50: 1.5 nM and 1.3 nM, respectively), and also inhibits TYRO3 (IC50: 6.7 nM). UNC8212 mediates polypharmacological properties by targeting the structurally diverse "back pocket" region of the TAM kinase family. UNC8212 binds tightly to TAM kinases and potently inhibits MERTK and AXL phosphorylation. UNC8212 has anti-tumor effects and can be used in cancer immunotherapy and tumor cell targeting research. -
loading...loading...
-
-
Axl-IN-17
0 ImagesCat. No.: HY-162085CAS No.: 3048409-80-6Axl-IN-17 (compound 13c) is an orally active, selective AXL inhibitor with an IC50 value of 3.2 nM. Axl-IN-17 reveals antitumor efficacy. -
loading...loading...
-
-
UNC3133
0 ImagesCat. No.: HY-115778CAS No.: 2011034-35-6 -
loading...loading...
-
- 1
